Emerging data suggest a possible genetic contributor to CIDP. In a recent study, patients with CIDP had a high frequency of perforin gene variations that impair the function of cytotoxic T and natural ...

CIDP causes muscle weakness and numbness, among other symptoms. Diagnosing CIDP involves peripheral nervous system testing, cerebrospinal fluid analysis, and imaging. CIDP is an immune-mediated ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...

The UAB Center for Pediatric-Onset Demyelinating Disease (CPODD) is one of the founding Pediatric Multiple Sclerosis (MS) Centers of Excellence in the country designated and funded in 2006 by the ...

Demyelination refers to damage to the myelin around nerves. Myelin coats many nerves in the body, but it can become damaged due to inflammation from viral infections, autoimmune diseases, and other ...

CIDP is a treatable condition that affects the peripheral nervous system. IVIG, plasma exchange, and corticosteroid therapy are the first-line treatment options, but a newer medication for adults has ...

Increasing evidence suggests that the severe gum disease, periodontitis, may contribute to central nervous system disorders ...

Identification and correct diagnosis of the chronic acquired demyelinating polyneuropathies is important because they are immune-mediated and, therefore, amenable to treatment Early diagnosis and ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) diagnoses are frequently missed or delayed and standard treatments -- intravenous immunoglobulin (IVIG), steroids, and plasma exchange -- are ...

Most of the nerves in your body are covered with a protective layer called myelin. It’s a lot like the insulation on electric wires. It helps messages from your brain move quickly and smoothly through ...

High levels of the periodontal bacterium Fusobacterium nucleatum may be associated with more severe disability in people with multiple sclerosis.